Literature DB >> 15878240

A survey of alternative transcripts of human tissue kallikrein genes.

Lisa Kurlender1, Carla Borgono, Iacovos P Michael, Christina Obiezu, Marc B Elliott, George M Yousef, Eleftherios P Diamandis.   

Abstract

Alternative splicing is prevalent within the human tissue kallikrein gene locus. Aside from being the most important source of protein diversity in eukaryotes, this process plays a significant role in development, physiology and disease. A better understanding of alternative splicing could lead to the use of gene variants as drug targets, therapeutic agents or diagnostic markers. With the rapidly rising number of alternative kallikrein transcripts, classifying new transcripts and piecing together the significance of existing data are becoming increasingly challenging. In this review, we present a systematic analysis of all currently known kallikrein alternative transcripts. By defining a reference form for each of the 15 kallikrein genes (KLK1 to KLK15), we were able to classify alternative splicing patterns. We identified 82 different kallikrein gene transcript forms, including reference forms. Alternative splicing may lead to the synthesis of 56 different protein forms for KLK1-15. In the kallikrein locus, the majority of alternative splicing events occur within the protein-coding region, and to a lesser extent in the 5' untranslated regions (UTRs). The most common alternative splicing event is exon skipping (35%) and the least common events are cryptic exons (3%) and internal exon deletion (3%). Seventy-six percent of kallikrein splice variants that are predicted to encode truncated proteins are the result of frameshifts. Eighty-nine percent of putative proteins encoded by splice variants are predicted to be secreted. Although several reports describe the identification of kallikrein splice variants and their potential clinical utility, this is the first extensive review on this subject. Accumulating evidence suggests that alternative kallikrein forms could be involved in many pathologic conditions or could have practical applications as biomarkers. The organization and analysis of the kallikrein transcripts will facilitate future work in this area and may lead to novel clinical and diagnostic applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878240     DOI: 10.1016/j.bbcan.2005.02.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  20 in total

1.  Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Authors:  Audrey Guillon-Munos; Katerina Oikonomopoulou; Noémie Michel; Chistopher R Smith; Agnès Petit-Courty; Sylvie Canepa; Pascale Reverdiau; Nathalie Heuzé-Vourc'h; Eleftherios P Diamandis; Yves Courty
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

2.  Structural characterization and expression of five novel canine kallikrein-related peptidases in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2010-09-19       Impact factor: 2.957

3.  A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells.

Authors:  John Lai; Melanie L Lehman; Marcel E Dinger; Stephen C Hendy; Tim R Mercer; Inge Seim; Mitchell G Lawrence; John S Mattick; Judith A Clements; Colleen C Nelson
Journal:  RNA       Date:  2010-04-20       Impact factor: 4.942

4.  The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2009-12-02       Impact factor: 2.957

5.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

6.  A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (KLK) locus.

Authors:  Carolyn A Goard; Irvin L Bromberg; Marc B Elliott; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

Review 7.  Functional roles of human kallikrein-related peptidases.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2009-10-09       Impact factor: 5.157

8.  Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact.

Authors:  Maroulio Talieri; Marina Devetzi; Andreas Scorilas; Eleana Pappa; Nikolaos Tsapralis; Ioannis Missitzis; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-02-21

9.  Genetic association of the KLK4 locus with risk of prostate cancer.

Authors:  Felicity Lose; Srilakshmi Srinivasan; Tracy O'Mara; Louise Marquart; Suzanne Chambers; Robert A Gardiner; Joanne F Aitken; Amanda B Spurdle; Jyotsna Batra; Judith A Clements
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

10.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Authors:  David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.